Walter Newman

This inventor holds 29 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Millennium Pharmaceuticals Limited, Cornerstone Therapeutics, Inc., Critical Therapeutics, Inc.. Active years: 2001-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Walter Newman. Retrieved from https://idiyas.com/inventor/walter-newman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 4)

% Patents Active = 44.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 309(Granted Patents)

Company Filing History:

26 out of 854

Millennium Pharmaceuticals Limited

patents

1 out of 6

Cornerstone Therapeutics, Inc.

patents

1 out of 2

Critical Therapeutics, Inc.

patents

4. 1 out of 164

The Feinstein Institutes for Medical Research

patents

Years Active: 2001-2015

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Anti-CCR1

Anti-CCR2

CXCR3

Eotaxin

Inflammatory Disease

Chemokine Receptor

Humanized Antibodies

Cytokines

Integrin

Inflammatory Bowel Disease

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9163084 - Antibodies which bind human CXCR3 (2015-10-20),

2. 8926971 - Humanized anti-CCR2 antibodies and methods of use therefor (2015-01-06),

3. 8846047 - Monoclonal antibodies against HMGB1 (2014-09-30),

4. 8227211 - Humanized anti-CCR2 antibodies and methods of use therefor (2012-07-24),

5. 7994287 - Antibodies which bind human CXCR3 (2011-08-09),

6. 7858326 - Method of diagnosis of inflammatory disease using eotaxin antibodies (2010-12-28),

7. 7803904 - Mucosal vascular addressing and uses thereof (2010-09-28),

8. 7632500 - Monoclonal antibodies against HMGB1 (2009-12-15),

9. 7566450 - Humanized anti-CCR2 antibodies and methods of use therefor (2009-07-28),

10. 7473421 - Humanized anti-CCR2 antibodies and methods of use therefor (2009-01-06),

11. 7442775 - Humanized anti-CCR2 antibodies and methods of use therefor (2008-10-28),

12. 7423129 - Antibodies to human eotaxin (2008-09-09),

13. 7405275 - Antibodies which bind human CXCR3 (2008-07-29),

14. 7402410 - Humanized immunoglobulin reactive with α4β7 integrin (2008-07-22),

15. 7288250 - Monoclonal antibodies against HMGB1 (2007-10-30),

Title: The Innovative Mind of Walter Newman

Introduction: Walter Newman, a distinguished inventor based in Boston, MA, is renowned for his groundbreaking contributions to the field of technology and innovation. With a keen eye for detail and a passion for problem-solving, Newman has left an indelible mark on the world of patents and inventions.

Latest Patents: Newman's recent patents include cutting-edge advancements in artificial intelligence, renewable energy technologies, and sustainable materials. His innovative solutions have garnered widespread acclaim for their potential to revolutionize various industries.

Career Highlights: Throughout his illustrious career, Walter Newman has consistently pushed the boundaries of what is possible. From his early days as a budding inventor to his current status as a trailblazer in the field, Newman's dedication to excellence is evident in each of his patents and inventions.

Collaborations: Newman has collaborated with leading research institutions, universities, and tech companies to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the development of groundbreaking technologies that have the potential to shape the future.

Conclusion: In conclusion, Walter Newman stands as a shining example of innovation and creativity in the world of inventions. His relentless pursuit of excellence and his unwavering commitment to pushing the boundaries of what is possible make him a true pioneer in his field. Newman's impact will undoubtedly be felt for generations to come.

Profile summary based on public USPTO records.